Experienced in Severe Congenital Neutropenia

Dr. Randolph B. Deger

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Virtua Medical Group, PA
200 Bowman Dr, Suite E325, 
Voorhees, NJ 
Accepting New Patients
Experienced in Severe Congenital Neutropenia
Virtua Medical Group, PA
200 Bowman Dr, Suite E325, 
Voorhees, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Randolph Deger is a Gynecologic Oncologist and an Oncologist in Voorhees, New Jersey. Dr. Deger is rated as an Experienced provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteral Reconstruction, and Hysterectomy. Dr. Deger is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NJ
Hospital Affiliations
West Jersey Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

VIRTUA MEDICAL GROUP, PA
200 Bowman Dr, Suite E325, Voorhees, NJ 08043

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials
Similar Doctors
Distinguished in Severe Congenital Neutropenia
Dr. Kush Sachdeva
Hematology | Oncology
Distinguished in Severe Congenital Neutropenia
Dr. Kush Sachdeva
Hematology | Oncology

Shore Memorial Hospital

1 E New York Ave, 
Somers Point, NJ 
 (40.5 miles away)
609-653-3500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kush Sachdeva is a Hematologist and an Oncologist in Somers Point, New Jersey. Dr. Sachdeva is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Severe Congenital Neutropenia, Agranulocytosis, Chronic Familial Neutropenia, and Thrombocytopenia.

Distinguished in Severe Congenital Neutropenia
Dr. Shailja Roy
Hematology Oncology | Hematology | Oncology
Distinguished in Severe Congenital Neutropenia
Dr. Shailja Roy
Hematology Oncology | Hematology | Oncology

Southern Oncology Hematology Assoc

1505 W Sherman Ave, Suite 101, 
Vineland, NJ 
 (28.1 miles away)
856-696-9550
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Shailja Roy is a Hematologist Oncology specialist and a Hematologist in Vineland, New Jersey. Dr. Roy is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. Her top areas of expertise are Hodgkin Lymphoma, Thrombocytopenia, Severe Congenital Neutropenia, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Roy is currently accepting new patients.

Distinguished in Severe Congenital Neutropenia
Dr. Benjamin P. Negin
Hematology | Oncology
Distinguished in Severe Congenital Neutropenia
Dr. Benjamin P. Negin
Hematology | Oncology

Shore Memorial Hospital

1 E New York Ave, 
Somers Point, NJ 
 (40.5 miles away)
609-653-3500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Benjamin Negin is a Hematologist and an Oncologist in Somers Point, New Jersey. Dr. Negin is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Severe Congenital Neutropenia, and Chronic Familial Neutropenia. Dr. Negin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Deger's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile